| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KDR |
| Uniprot No | P35968 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-764aa |
| 氨基酸序列 | ASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLE |
| 预测分子量 | 112.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于KDR(VEGFR2)重组蛋白的模拟参考文献示例，基于常见研究方向合理推测内容：
---
1. **文献名称**: "Expression and Functional Characterization of Recombinant Human KDR/VEGFR2 in Mammalian Cells"
**作者**: Smith A, et al.
**摘要**: 本研究报道了在HEK293细胞中高效表达并纯化功能性重组人KDR蛋白的方法。通过表面等离子体共振(SPR)分析，证实重组KDR与VEGF-A配体具有高亲和力结合，并验证其体外激酶活性，为靶向药物筛选提供工具。
2. **文献名称**: "Structural Basis of KDR Activation by VEGF Revealed by Cryo-EM"
**作者**: Johnson B, et al.
**摘要**: 利用冷冻电镜技术解析了重组KDR蛋白与VEGF复合物的三维结构，揭示了配体诱导的二聚化及激酶结构域构象变化，为设计选择性VEGFR2抑制剂提供结构基础。
3. **文献名称**: "Recombinant KDR Extracellular Domain as a Potent Inhibitor of Tumor Angiogenesis"
**作者**: Lee C, et al.
**摘要**: 构建了KDR胞外段重组蛋白(sKDR)，证明其可通过竞争性结合VEGF阻断内皮细胞增殖和血管生成，在动物模型中显著抑制肿瘤生长，提示其作为抗血管治疗药物的潜力。
4. **文献名称**: "Kinetic Analysis of KDR Signaling Using a Biosensor-Based Approach"
**作者**: Zhang Y, et al.
**摘要**: 开发基于重组KDR的荧光生物传感器，实时监测VEGF诱导的受体磷酸化及下游信号通路动态，揭示KDR激活的时空调控机制。
---
**备注**：以上为模拟文献，实际文献需通过PubMed、Web of Science或Google Scholar检索关键词(如“recombinant KDR protein”、“VEGFR2 expression”)。建议结合具体研究领域筛选近年高引论文。
**Background of KDR Recombinant Protein**
KDR (kinase insert domain receptor), also known as vascular endothelial growth factor receptor 2 (VEGFR2), is a transmembrane tyrosine kinase receptor primarily expressed on endothelial cells. It plays a pivotal role in angiogenesis, the process of new blood vessel formation, by binding to ligands such as VEGF-A, VEGF-C, and VEGF-D. Upon ligand activation, KDR undergoes dimerization and autophosphorylation, triggering downstream signaling pathways like RAS/MAPK and PI3K/AKT, which promote endothelial cell proliferation, migration, and survival. Dysregulation of KDR signaling is implicated in pathological conditions, including cancer, retinopathy, and inflammatory diseases, making it a critical therapeutic target.
Recombinant KDR protein is engineered in vitro using expression systems (e.g., mammalian or insect cells) to produce soluble, functional forms of the receptor. These proteins typically retain key domains, such as the extracellular ligand-binding region, enabling studies on VEGF-KDR interactions. Researchers use KDR recombinant proteins to investigate signaling mechanisms, screen for inhibitory drugs, or develop diagnostic tools. For example, in cancer research, blocking KDR-VEGF interactions can suppress tumor angiogenesis, a strategy leveraged in therapies like bevacizumab.
The production of recombinant KDR involves codon optimization, affinity purification (e.g., via Fc tags), and validation through assays like ELISA or surface plasmon resonance to confirm ligand-binding activity. Its applications extend to basic research, drug discovery, and biomanufacturing, offering insights into vascular biology and aiding the development of targeted therapies. Quality control ensures batch-to-batch consistency, critical for experimental reproducibility and clinical translation. Overall, KDR recombinant proteins serve as indispensable tools for unraveling angiogenesis-related pathways and advancing biomedical innovations.
×
